Which baseline blood tests are required before initiating methotrexate therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Baseline Blood Tests Required Before Starting Methotrexate

Before initiating methotrexate therapy, you must obtain: complete blood count (CBC) with differential, liver function tests (AST, ALT, albumin), serum creatinine with calculated creatinine clearance, and a chest X-ray (if not done within the past year). 1

Essential Baseline Laboratory Tests

Mandatory Tests

  • Complete blood count (CBC) with differential and platelet count - to establish baseline hematologic function and detect pre-existing cytopenias 1, 2, 3, 4
  • Liver function tests:
    • AST (aspartate aminotransferase)
    • ALT (alanine aminotransferase)
    • Albumin
    • Alkaline phosphatase and bilirubin 1, 5, 2, 4
  • Renal function:
    • Serum creatinine with calculated creatinine clearance (must be >60 mL/min before starting) 1, 3, 4, 6
    • BUN (blood urea nitrogen) 3

Strongly Recommended Additional Tests

  • Hepatitis B and C serology - to identify chronic viral hepatitis that increases hepatotoxicity risk 1, 5, 2, 6
  • Chest X-ray (if not obtained within the previous year) - baseline pulmonary assessment 1
  • Pregnancy test for women of childbearing potential - methotrexate is absolutely contraindicated in pregnancy 1, 5

Tests to Consider Based on Risk Factors

  • HIV serology 1
  • Fasting blood glucose and lipid profile - particularly relevant given psoriasis and RA comorbidities 1
  • Non-invasive liver fibrosis assessment (FIB-4 score, followed by elastography if indicated) for patients with hepatotoxicity risk factors including obesity (BMI ≥30), diabetes, hyperlipidemia, alcohol use, or history of liver disease 2, 7, 8

Critical Pre-Treatment Clinical Assessment

Beyond laboratory tests, you must conduct a thorough clinical evaluation:

  • Alcohol intake history - quantify consumption as this significantly increases hepatotoxicity risk 1, 5
  • Medication review - identify potential drug interactions, especially NSAIDs, sulfonamides, probenecid, and other hepatotoxic or nephrotoxic agents 4
  • Respiratory symptoms and history - pulmonary disease increases risk of methotrexate pneumonitis 5, 8
  • Risk factors for liver disease - prior hepatotoxic drug exposure, family history of inheritable liver disease (Wilson disease, hemochromatosis, α-1 antitrypsin deficiency) 5, 2

Important Caveats

Do not delay methotrexate initiation for non-invasive liver fibrosis testing - this can be performed concurrently with treatment start in appropriate patients 7. However, methotrexate is absolutely contraindicated if baseline creatinine clearance is <60 mL/min or in patients with cirrhosis 4.

The 2020 AAD-NPF guidelines 2 represent the most recent high-quality evidence and notably no longer recommend routine baseline liver biopsy, even in patients with risk factors - a significant departure from older dermatology practice. Instead, they advocate for non-invasive assessment with FIB-4 scoring and elastography when indicated.

Patient education is mandatory before prescribing - emphasize weekly (not daily) dosing, as accidental daily administration has caused fatal toxicity 8, 4. Ensure patients understand they need effective contraception and must avoid conception for at least 3 months after stopping methotrexate 1, 2.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.